Carrier-mediated delivery of peptidic drugs for cancer therapy

Peptides

Volumn 27, Issue 11, 2006, Pages 3020-3028

  Dass, Crispin R ^a   Choong, Peter F M ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Cancer; Drug delivery; Liposome; Microparticle; Peptide; Protein

Indexed keywords

'BIOSPHERE'; ALPHA2B INTERFERON; CHOLESTEROL; CHOLESTEROL HYDROGEN SUCCINATE; CPG OLIGODEOXYNUCLEOTIDE; DAUNORUBICIN; DISTEAROYLPHOSPHATIDYLCHOLINE; DOXORUBICIN; ENFUVIRTIDE; FREUND ADJUVANT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN GROWTH HORMONE; INSULIN; LIPOSOME; M6 PEPTIDE; MACROGOL; OVALBUMIN; PENETRATIN; PEPTIDE DERIVATIVE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLGLYCEROL; PHOSPHATIDYLSERINE; PHOSPHORYL LIPID A; POLYETHYLENEGLYCOL PHOSPHATIDYLETHANOLAMINE; POLYGLACTIN; POLYLACTIC ACID; PROTEINASE INHIBITOR; RECOMBINANT INTERLEUKIN 12; SPHINGOMYELIN; TECHNOSPHERE; THERASPHERE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CANCER THERAPY; CD4+ T LYMPHOCYTE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; GENE THERAPY; GENE VECTOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; IMMUNE RESPONSE; IMMUNIZATION; LUNG METASTASIS; MAXIMUM TOLERATED DOSE; NANOPARTICLE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; REVIEW; STROKE; TUMOR GROWTH; TUMOR IMMUNITY;

DRUG CARRIERS; HUMANS; LIPOSOMES; MICROSPHERES; NEOPLASMS; PEPTIDES;

EID: 33750971440     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2006.05.020     Document Type: Review

References (46)

1. Allen T.M., and Cullis P.R. Drug delivery systems: entering the mainstream. Science 303 (2004) 1818-1822
2. Cao G., Pei W., Ge H., Liang Q., Luo Y., Sharp F.R., et al. In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J Neurosci 22 (2002) 5423-5431
3. Chang J.S., Choi M.J., Cheong H.S., and Kim K. Development of Th1-mediated CD8+ effector T cells by vaccination with epitope peptides encapsulated in pH-sensitive liposomes. Vaccine 19 (2001) 3608-3614
4. Dass C.R., and Burton M.A. Modified microplex vector enhances transfection of cells in culture while maintaining tumour-selective gene delivery in-vivo. J Pharm Pharmacol 55 (2003) 19-25
5. Dass C.R., and Su T. Particle-mediated intravascular delivery of oligonucleotides to tumors: associated biology and lessons from genotherapy. Drug Deliv 8 (2001) 191-213
6. Dass C.R., Walker T.L., Burton M.A., and DeCruz E.E. Enhanced anticancer therapy mediated by specialised liposomes. J Pharm Pharmacol 49 (1997) 972-975
7. Dass C.R., Walker T.L., Kalle W.H., and Burton M.A. A microsphere-liposome (microplex) vector for targeted gene therapy of cancer. II: In vivo biodistribution study in a solid tumor model. Drug Deliv 7 (2000) 15-19
8. Derossi D., Calvet S., Trembleau A., Brunissen A., Chassaing G., and Prochiantz A. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem 271 (1996) 18188-18193
9. Dietz G.P., Kilic E., and Bahr M. Inhibition of neuronal apoptosis in vitro and in vivo using TAT-mediated protein transduction. Mol Cell Neurosci 21 (2002) 29-37
10. During M.J., Symes C.W., Lawlor P.A., Lin J., Dunning J., Fitzsimons H.L., et al. An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. Science 287 (2000) 1453-1460
11. Edwards D.A., Hanes J., Caponetti G., Hrkach J., Ben-Jebria A., Eskew M.L., et al. Large porous particles for pulmonary drug delivery. Science 276 (1997) 1868-1871
12. Egilmez N.K., Jong Y.S., Sabel M.S., Jacob J.S., Mathiowitz E., and Bankert R.B. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res 60 (2000) 3832-3837
13. Gabizon A., Shmeeda H., and Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 42 (2003) 419-436
14. Hess S.D., Egilmez N.K., Bailey N., Anderson T.M., Mathiowitz E., Bernstein S.H., et al. Human CD4+ T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-gamma. J Immunol 170 (2003) 400-412
15. Hill H.C., Conway Jr. T.F., Sabel M.S., Jong Y.S., Mathiowitz E., Bankert R.B., et al. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res 62 (2002) 7254-7263
16. Hillery A.M., Jani P.U., and Florence A.T. Comparative, quantitative study of lymphoid and non-lymphoid uptake of 60 nm polystyrene particles. J Drug Target 2 (1994) 151-156
17. Huang S.K., Lee K.D., Hong K., Friend D.S., and Papahadjopoulos D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res 52 (1992) 5135-5143
18. Huminiecki L., Gorn M., Suchting S., Poulsom R., and Bicknell R. Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis. Genomics 79 (2002) 547-552
19. Ignatius R., Mahnke K., Rivera M., Hong K., Isdell F., Steinman R.M., et al. Presentation of proteins encapsulated in sterically stabilized liposomes by dendritic cells initiates CD8(+) T-cell responses in vivo. Blood 96 (2000) 3505-3513
20. Justin-Temu M., Damian F., Kinget R., and Van Den Mooter G. Intravaginal gels as drug delivery systems. J Womens Health (Larchmt) 13 (2004) 834-844
21. Kilic E., Dietz G.P., Hermann D.M., and Bahr M. Intravenous TAT-Bcl-Xl is protective after middle cerebral artery occlusion in mice. Ann Neurol 52 (2002) 617-622
22. Kondo E., Seto M., Yoshikawa K., and Yoshino T. Highly efficient delivery of p16 antitumor peptide into aggressive leukemia/lymphoma cells using a novel transporter system. Mol Cancer Ther 3 (2004) 1623-1630
23. Ladner R.C., Sato A.K., Gorzelany J., and de Souza M. Phage display-derived peptides as therapeutic alternatives to antibodies. Drug Discov Today 9 (2004) 525-529
24. Li W.M., Dragowska W.H., Bally M.B., and Schutze-Redelmeier M.P. Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine 21 (2003) 3319-3329
25. Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65 (2000) 271-284
26. Masuda T., Furue M., and Matsuda T. Photocured, styrenated gelatin-based microspheres for de novo adipogenesis through corelease of basic fibroblast growth factor, insulin, and insulin-like growth factor I. Tissue Eng 10 (2004) 523-535
27. Mathiowitz E., Jacob J.S., Jong Y.S., Carino G.P., Chickering D.E., Chaturvedi P., et al. Biologically erodable microspheres as potential oral drug delivery systems. Nature 386 (1997) 410-414
28. Mikkelsen-Lynch P., Butler J., Huerta D., Tsals I., Davidson D., and Hamm S. A pharmacokinetic and tolerability evaluation of two continuous subcutaneous infusion systems compared to an oral controlled-release morphine. J Pain Symptom Manage 19 (2000) 348-356
29. Northfelt D.W., Martin F.J., Working P., Volberding P.A., Russell J., Newman M., et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 36 (1996) 55-63
30. Oh P., Li Y., Yu J., Durr E., Krasinska K.M., Carver L.A., et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 429 (2004) 629-635
31. Patton J.S., Bukar J.G., and Eldon M.A. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 43 (2004) 781-801
32. Peters B.G., Goeckner B.J., Ponzillo J.J., Velasquez W.S., and Wilson A.L. Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment. Formulary 30 (1995) 388-393
33. Rousselle C., Clair P., Smirnova M., Kolesnikov Y., Pasternak G.W., Gac-Breton S., et al. Improved brain uptake and pharmacological activity of dalargin using a peptide-vector-mediated strategy. J Pharmacol Exp Ther 306 (2003) 371-376
34. Sabel M.S., Hill H., Jong Y.S., Mathiowitz E., Bankert R.B., and Egilmez N.K. Neoadjuvant therapy with interleukin-12-loaded polylactic acid microspheres reduces local recurrence and distant metastases. Surgery 130 (2001) 470-478
35. Sabel M.S., Skitzki J., Stoolman L., Egilmez N.K., Mathiowitz E., Bailey N., et al. Intratumoral IL-12 and TNF-alpha-loaded microspheres lead to regression of breast cancer and systemic antitumor immunity. Ann Surg Oncol 11 (2004) 147-156
36. Schwarze S.R., Ho A., Vocero-Akbani A., and Dowdy S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285 (1999) 1569-1572
37. Shibata H., Nakagawa S., Mayumi T., and Tsutsumi Y. Development of novel drug delivery system (DDS) technologies for proteomic-based drug development. Biol Pharm Bull 27 (2004) 1483-1488
38. Smith D.H., Adams J.R., Johnston S.R., Gordon A., Drummond M.F., and Bennett C.L. A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK. Ann Oncol 13 (2002) 1590-1597
39. Temsamani J., and Vidal P. The use of cell-penetrating peptides for drug delivery. Drug Discov Today 9 (2004) 1012-1019
40. Torchilin V.P., Levchenko T.S., Rammohan R., Volodina N., Papahadjopoulos-Sternberg B., and D'Souza G.G. Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc Natl Acad Sci USA 100 (2003) 1972-1977
41. Vocero-Akbani A., Heyden N.V., Lissy N.L., Ratner L., and Dowdy S.F. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med 4 (1999) 1449-1452
42. Wadia J.S., and Dowdy S.F. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev 57 (2005) 579-596
43. Woodle M.C., Storm G., Newman M.S., Jekot J.J., Collins L.R., Martin F.J., et al. Prolonged systemic delivery of peptide drugs by long-circulating liposomes: illustration with vasopressin in the Brattleboro rat. Pharm Res 9 (1992) 260-265
44. Wu N.Z., Da D., Rudoll T.L., Needham D., Whorton A.R., and Dewhirst M.W. Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res 53 (1993) 3765-3770
45. Xu R., Rahimi M., Ma H., Fung P., Chang C., Xu S., et al. Stability of infectious recombinant adeno-associated viral vector in gene delivery. Med Sci Monit 11 (2005) 305-308
46. Zangemeister-Wittke U. Antibodies for targeted cancer therapy-technical aspects and clinical perspectives. Pathobiology 72 (2005) 279-286